Filing Flows › Acadia Pharmaceuticals (ACAD) › Net income
Acadia Pharmaceuticals (ACAD) net income by quarter
Acadia Pharmaceuticals' net income was $53.5M in Q3 2026 (third quarter 2026), +70% from Q2 2026. Over the last 6 quarters it ranged from $19.0M (Q1 2025) to $274M (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $53.5M | +70% | -25% |
| Q2 2026 | $31.5M | -88% | +18% |
| Q4 2025 | $274M | +281% | — |
| Q3 2025 | $71.8M | +169% | — |
| Q2 2025 | $26.7M | +40% | — |
| Q1 2025 | $19.0M | — | — |
Q3 2026 at a glance
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Acadia Pharmaceuticals' net income?
Acadia Pharmaceuticals' net income was $53.5M in Q3 2026 (third quarter 2026), +70% from Q2 2026.
How has Acadia Pharmaceuticals' net income changed?
Over the last 6 quarters it ranged from $19.0M (Q1 2025) to $274M (Q4 2025).
Q3 2026 results → · How Acadia Pharmaceuticals makes money →